DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injuries and chronic liver diseases by developing new and life-saving treatments based on its structured self-genetic program. DUR-928, the company's leading drug candidate for possible treatment of alcohol-related hepatitis (AH) granted by the FDA fast track designation, covid-19 patients, and non-alcoholic hepatitis (NASH). DURECT special drug delivery techniques are designed to enable new indicators and enhanced features for small drugs and biological molecules. One of the candidates for the late-stage product in this category is POSIMIR® (bupivacaine sustainable release solution), a locally investigated, non-opioid analgesic designed to provide up to three days of continuous pain relief after surgery. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.